Haleon plc (LON:HLN) Given Average Recommendation of “Moderate Buy” by Brokerages

Haleon plc (LON:HLN) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is GBX 398.67.

Several equities analysts have weighed in on the company. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a report on Thursday, April 30th. Jefferies Financial Group reduced their price objective on Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a report on Tuesday. Berenberg Bank reissued a “buy” rating and set a GBX 512 price objective on shares of Haleon in a report on Thursday, April 30th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a report on Thursday, January 22nd.

Insiders Place Their Bets

In other Haleon news, insider Brian McNamara sold 704,974 shares of the stock in a transaction on Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total transaction of £2,594,304.32. Company insiders own 0.01% of the company’s stock.

Haleon Stock Performance

HLN stock opened at GBX 331.20 on Friday. The firm has a market cap of £29.44 billion, a PE ratio of 17.90, a P/E/G ratio of 1.49 and a beta of 0.25. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26. The business has a 50 day moving average of GBX 367 and a 200-day moving average of GBX 370.77. Haleon has a 12-month low of GBX 325.10 and a 12-month high of GBX 419.50.

Haleon (LON:HLN) last released its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.43% and a net margin of 12.59%. As a group, sell-side analysts expect that Haleon will post 19.5033282 earnings per share for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.